Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - solution for injection - trastuzumab 60 mg/ml; pertuzumab 60 mg/ml - pertuzumab and trastuzumab - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy for:•the neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer .•the adjuvant treatment of patients with her2-positive early breast cancer (node positive) at high risk of recurrence.metastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - pertuzumab - infusion, solution concentrate - 30 mg/ml - pertuzumab 30 mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - pertuzumab - solution for infusion - 30mg/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

roche diagnostics gmbh - pertuzumab - concentrate for solution for infusion - 30mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - pertuzumab - concentrate for solution for infusion - 30mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pertuzumab 80 mg/ml; trastuzumab 40 mg/ml;   - solution for injection - active: pertuzumab 80 mg/ml trastuzumab 40 mg/ml   excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 sucrose trehalose dihydrate water for injection - early breast cancer phesgo is indicated in combination with chemotherapy for: - neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. - adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. metastatic breast cancer phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pertuzumab 60 mg/ml; trastuzumab 60 mg/ml;   - solution for injection - active: pertuzumab 60 mg/ml trastuzumab 60 mg/ml   excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 sucrose trehalose dihydrate water for injection - early breast cancer phesgo is indicated in combination with chemotherapy for: - neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. - adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. metastatic breast cancer phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - gemtuzumab ozogamicin 5mg - powder for injection - 5 mg - active: gemtuzumab ozogamicin 5mg excipient: dextran 40 dibasic sodium phosphate monobasic sodium phosphate monohydrate sodium chloride sucrose - mylotarg is indicated for combination therapy with standard anthracycline and cytarabine (arac) for the treatment of patients age 15 years and above with previously untreated, de novo cd33-positive acute myeloid leukaemia (aml), except acute promyelocytic leukaemia (apl).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - inotuzumab ozogamicin 1mg - powder for injection - 1 mg - active: inotuzumab ozogamicin 1mg excipient: polysorbate 80 sodium chloride sucrose trometamol - besponsa is indicated for the treatment of adults with relapsed or refractory cd22-positive b-cell precursor acute lymphoblastic leukaemia (all).

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

f. hoffmann-la roche s.a. - pertuzumab - pertuzumab....420 mg